Current Treatment Options for Primary Biliary Cholangitis

Kimberly A. Wong, Runalia Bahar, Chung H. Liu, Christopher Bowlus

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Primary biliary cholangitis is a progressive, autoimmune disease of the interlobular bile ducts, leading to secondary damage of hepatocytes that may progress to cirrhosis and liver failure. Until recently, the only approved treatment was ursodeoxycholic acid. However, 40% of patients do not have an adequate response. Obeticholic acid was approved for treatment as add-on therapy in this group of patients. Off-label use of fibrates has also been reported to be effective. Several new therapies are in development and may further add to the treatment options available to patients with primary biliary cholangitis.

Original languageEnglish (US)
JournalClinics in Liver Disease
DOIs
StateAccepted/In press - Jan 1 2018

    Fingerprint

Keywords

  • Autoimmune liver disease
  • Bile acids
  • Farnesoid X receptor
  • Therapy

ASJC Scopus subject areas

  • Hepatology

Cite this